**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Toas and Knapp

Confirmation No. 5057

Serial No.: 10/772,063

Group Art Unit: 1771

Filed: February 4, 2004

Examiner: Matzek, Matthew D.

For: Insulation Product Having Antimicrobial/Antifungal Facing, Facing for Same,  
and Process for Making Same

I CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED  
WITH THE U.S. POSTAL SERVICE AS FIRST CLASS MAIL IN AN  
ENVELOPE ADDRESSED TO THE COMMISSIONER FOR PATENTS,  
P.O. BOX 1450, ALEXANDRIA, VA 22313.

ON

November 22, 2004

BY

Mary La Grange

M.S. Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER**

Enclosed herewith is an Information Disclosure Statement pursuant to 37 CFR. § 1.56 in  
connection with the above-identified application, which statement is being filed:

☐ Together with the present application.

☐ Before the first Office Action on the merits or three (3) months from the  
filing date of this application, whichever occurs last. [37 CFR § 1.97(b)]

☒ After the first Office Action on the merits, but before a Final Office  
Action under §1.113 or Notice of Allowance under §1.311, whichever occurs first. [37 CFR  
§1.97(c)]. (Either the fee or certification is provided, as set forth below).

☐ After a Final Office Action under §1.113 or Notice of Allowance under  
§1.311, but prior to or with payment of the Issue Fee. [37 CFR §1.97(d)]. The fee and  
certification are provided, as set forth below).

Consistent with Applicant's obligations pursuant to 37 CFR §§1.97 and 1.98, the following requirements have been met:

☐ No separate requirements are needed.

☐ No additional fee is required.

**Fee Under 37 CFR § 1.97(c) or 1.97(d)**

☒ The fee of \$180.00 for submission of an IDS under § 1.97(c) as set forth in § 1.17(p) accompanies this statement.

**Certification Under 37 CFR § 1.97(e)**

The undersigned certifies:

☐ 1 that each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

☒ 2 that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement.

**Provision of Copies of References**

☐ A copy of each of the references listed on the attached Form PTO-1449 is enclosed herewith and forms a part hereof.

☐ A translation of Reference \_\_\_\_ is enclosed herewith and forms a part hereof.

☐ A copy of the European Search Report from a corresponding or related EPO application is enclosed herewith.

☐ A copy of the International Search Report from a corresponding or related PCT application is enclosed herewith.

☐ Copies of Foreign Patent Documents and Other Documents provided.


**Identification of Prior Application(s) In Which Listed Information Was Already Cited And For Which No Copies Are Submitted Or Need Be Submitted**

☐ This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior U.S. Application No(s). , filed . The following references were submitted to, and/or cited by, the Office in the prior application(s) and therefore are not required to be provided in this application:

The Commissioner is hereby authorized to charge any fees associated with this communication or credit any overpayment to Deposit Account No. 04-1679.

Date: 11.22.04

Respectfully submitted,




Peter J. Cronk

Registration No. 32,021

DUANE MORRIS LLP  
One Liberty Place  
Philadelphia, PA 19103-7396  
215-979-1252 tel  
215-979-1020 fax

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i> Sheet 1 of 1	ATTY. DOCKET NO. D0932-00447	APPLICATION NO. 10/772,063
	FIRST NAMED APPLICANT Toas and Knapp	EXAMINER Matzek, Matthew D.
	FILING DATE February 4, 2004	GROUP 1771



## U.S. PATENT DOCUMENTS

EXAMINER INITIALS	Cite No.	DOCUMENT NUMBER	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	A	US2004/0185211A1	Fay et al.	09/23/2004	

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS	Cite No.	Office	DOCUMENT NUMBER	COUNTRY	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T

## OTHER DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.
	B	Rohm and Haas, Markets and Products, Kathon® and Neolone™, Trade Literature, pp 1-3, 11/2004
	C	Rohm and Haas, Markets and Products, Personal Care, Kathon® CG and Kathon® CG II, Trade Literature, pp 1-2, 11/2004
	D	Rohm and Haas, Markets and Products, Pulp and Paper, Trade Literature, pp 1-2, 11/2004
	E	Rohm and Haas, Environmental Achievements, Dissipation of Kathon® WT biocide by degradation and dilution throughout the papermaking process, Trade Literature, pp 1-3, 11/2004
	F	PAN Pesticides Database – Pesticide Products, Google Product Search Results, pp 1-5, 11/2004
EXAMINER SIGNATURE		DATE CONSIDERED